Barrett's esophagus future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Pal Manickam (talk | contribs) |
Amresh Kumar (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
* Biomarkers | * Biomarkers | ||
# Can not be used to confirm the diagnosis of Barrett´s esophagus. | # [[Can]] [[not]] [[be]] [[used]] [[to]] [[confirm]] [[the]] [[diagnosis]] [[of]] [[Barrett´s esophagus]]. | ||
# Can not be used to predict risk of progression. | # [[Can]] [[not]] [[be]] [[used]] [[to]] [[predict]] [[risk]] [[of]] [[progression]]. | ||
# | # [[Promising]] [[for]] [[the]] [[future]]<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | ||
* Endoscopic Therapy | * Endoscopic Therapy | ||
# In patients with confirmed high-grade dysplasia with Barrett' esophagus it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance. | # [[In]] [[patients]] [[with]] [[confirmed]] [[high-grade]] [[dysplasia]] [[with]] [[Barrett' esophagus]], [[it]] [[is]] [[more]] [[recommended]] [[to]] [[proceed]] [[with]] [[endoscopic]] [[eradication]] [[therapy]] [[with]] [[radiofrequency]] [[ablation]] ([[RFA]]), [[photodynamic]] [[therapy]] ([[PDT]]), [[or]] [[endoscopic]] [[mucosal]] [[resection]] ([[EMR]]) [[rather]] [[than]] [[surveillance]]. | ||
# In patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | # [[In]] [[patients]] [[who]] [[have]] [[dysplasia]] [[in]] [[Barrett's esophagus]] [[associated]] [[with]] [[a]] [[visible]] [[mucosal]] [[irregularity]] [[it]] [[is]] [[recommended]] [[to]] [[proceed]] [[with]] [[endoscopic]] [[mucosal]] [[resection]] ([[EMR]]) [[to]] [[determine]] [[the]] [[T stage]] [[of]] [[the]] [[neoplasia]]<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref>. | ||
==References== | ==References== | ||
Revision as of 18:59, 7 November 2017
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus future or investigational therapies |
|
FDA on Barrett's esophagus future or investigational therapies |
|
CDC on Barrett's esophagus future or investigational therapies |
|
Barrett's esophagus future or investigational therapies in the news |
|
Blogs on Barrett's esophagus future or investigational therapies |
|
Risk calculators and risk factors for Barrett's esophagus future or investigational therapies |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
- Biomarkers
- Can not be used to confirm the diagnosis of Barrett´s esophagus.
- Can not be used to predict risk of progression.
- Promising for the future[1].
- Endoscopic Therapy
- In patients with confirmed high-grade dysplasia with Barrett' esophagus, it is more recommended to proceed with endoscopic eradication therapy with radiofrequency ablation (RFA), photodynamic therapy (PDT), or endoscopic mucosal resection (EMR) rather than surveillance.
- In patients who have dysplasia in Barrett's esophagus associated with a visible mucosal irregularity it is recommended to proceed with endoscopic mucosal resection (EMR) to determine the T stage of the neoplasia[1].
References
- ↑ 1.0 1.1 Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). "American Gastroenterological Association medical position statement on the management of Barrett's esophagus". Gastroenterology. 140 (3): 1084–91. doi:10.1053/j.gastro.2011.01.030. PMID 21376940. Unknown parameter
|month=ignored (help)